The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
A Pilot Randomized Trial of Carbamazepine for Behavioral Symptoms in Treatment-Resistant Outpatients with Alzheimer Disease
Abstract
The authors performed a 6-week, randomized, double-blind, placebo-controlled, parallel-group trial of carbamazepine (400 mg/day) with 21 agitated subjects (16 completers) who had been treated unsuccessfully with antipsychotics. There was greater improvement for the carbamazepine group on the Clinical Global Impression of Change (P=0.055) and the Brief Psychiatric Rating Scale (BPRS) Hostility item (P=0.009), with a trend toward worsening on the BPRS Hallucination item (P=0.067). Overall, carbamazepine showed modest clinical benefit in these subjects, who had not responded to antipsychotics, and particular benefit for hostility. The effect on global ratings was similar to those found in an earlier report in nursing home residents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Two small trials of carbamazepine (n=51 and n=21) of less than six weeks’ duration showed some benefit for agitation and global clinical outcomes.143 144”
From Assessment and management of behavioral and psychological symptoms of dementia (2015) · cites this paper as [144]
Citations
Cites
Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living
Lawton, M. P., & Brody, E. M. (1969) · The Gerontologist · doi:10.1093/geront/9.3_part_1.179 · Cited by 18,540
Efficacy and Tolerability of Carbamazepine for Agitation and Aggression in Dementia
Tariot, P. N., Erb, R., Podgorski, C. A., Cox, C., Patel, S., Jakimovich, L., & Irvine, C. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.1.54 · Cited by 422
Flagged first, then by citations
Research works printed but not linked: 15
- Schneider, 1997, Eligibility of Alzheimer's disease clinic patients for clinical trials, J Am Geriatr Soc, 45, 923, 10.1111/j.1532-5415.1997.tb02960.x · DOI
- Tariot, 1995, Anticonvulsant and other non-neuroleptic treatment of agitation in dementia, J Geriatr Psychiatry Neurol, 8, S28, 10.1177/089198879500800105 · DOI
- Schneider, 1990, A metaanalysis of controlled trials of neuroleptic treatment in dementia, J Am Geriatr Soc, 38, 553, 10.1111/j.1532-5415.1990.tb02407.x · DOI · Paper page
- Katz, 1999, Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial: Risperidone Study Group, J Clin Psychiatry, 60, 107, 10.4088/JCP.v60n0207 · DOI
- Street J, Clark WS, Gannon KS, Olanzapine reduces psychosis and behavioral disturbances associated with Alzheimer's disease. Presentation of the 9th Congress of the International Psychogeriatric Association, August 15–20, 1999, Vancouver, BC, Canada · DOI
- Schneider, 1991, Non-neuroleptic medication in the management of agitation in Alzheimer's disease and other dementia: a selective review, Int J Geriatr Psychiatry, 6, 691, 10.1002/gps.930061003 · DOI
- Stefani, 1997, Voltage-activated calcium channels: targets of anti-epileptic drug therapy?, Epilepsia, 38, 959, 10.1111/j.1528-1157.1997.tb01477.x · DOI
- Gleason, 1990, Carbamazepine treatment of agitation in Alzheimer's outpatients refractory to neuroleptics, J Clin Psychiatry, 51, 115
- Tariot, 1994, Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study, J Am Geriatr Soc, 42, 1160, 10.1111/j.1532-5415.1994.tb06982.x · DOI
- Olin, 1997, A comparative analysis of Spanish- and English-speaking Alzheimer's disease patients: eligibility and interest in clinical drug trials, Journal of Clinical Geropsychology, 3, 183
- Overall, 1988, Introduction to the Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling, Psychopharmacol Bull, 24, 97
- McKhann, 1984, Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
- Folstein, 1975, Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res, 12, 189, 10.1016/0022-3956(75)90026-6 · DOI · Paper page
- Hamilton, 1960, A rating scale for depression, J Neurol Neurosurg Psychiatry, 23, 56, 10.1136/jnnp.23.1.56 · DOI · Paper page
- Lawton, 1988, Instrumental Activities of Daily Living (IADL) Scale: original observer-rated version, Psychopharmacol Bull, 24, 785
Cited by
Sorted by citations
Assessment and management of behavioral and psychological symptoms of dementia
Kales, H. C., Gitlin, L. N., & Lyketsos, C. G. (2015) · BMJ · doi:10.1136/bmj.h369 · Cited by 1,247
Management of agitation and aggression associated with Alzheimer disease
Ballard, C. G., Gauthier, S., Cummings, J. L., Brodaty, H., Grossberg, G. T., Robert, P., & Lyketsos, C. G. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.39 · Cited by 404
Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future
Geda, Y. E., Schneider, L. S., Gitlin, L. N., Miller, D. S., Smith, G. S., Bell, J., Evans, J., Lee, M., Porsteinsson, A., Lanctôt, K. L., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.12.001 · Cited by 378
Self-citationLanctôt, K. L., Herrmann, N., Mazzotta, P., Khan, L. R., & Ingber, N. (2004) · The Canadian Journal of Psychiatry · doi:10.1177/070674370404900705 · Cited by 191
Management of Neuropsychiatric Symptoms in People with Dementia
Ballard, C., & Corbett, A. (2010) · CNS Drugs · doi:10.2165/11319240-000000000-00000 · Cited by 147
Metadata
- Authors
- Olin, J. T., Fox, L. S., Pawluczyk, S., Taggart, N. A., & Schneider, L. S.
- Affiliations
- National Institute of Mental Health (US)
- Corresponding author
- Olin, Jason T.
- Venue
- The American Journal of Geriatric Psychiatry
- Publisher
- Elsevier BV
- Published
- 2001-09
- Volume
- 9
- Issue
- 4
- Pages
- 400-405
- ISSN
- 1064-7481 (ISSN-L)
- OpenAlex
- W2002993996
- Cited by
- 163
- References
- 2
- Citations by year
- 2026: 3 · 2025: 4 · 2024: 4 · 2023: 3 · 2022: 29 · 2021: 11 · 2020: 5 · 2019: 6 · 2018: 9 · 2017: 3 · 2016: 4 · 2015: 4 · 2014: 5 · 2013: 5 · 2012: 6
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- American Journal of Geriatric Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01mh048759-04, 5k07mh001368-04)
- National Institute on Aging (AG 05142, P50AG005142)
- National Institute of Mental Health (MH 48759, MH 01368)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- carbamazepine, Alzheimer's disease, behavioral symptoms, agitation, hostility, anticonvulsant therapy, outpatients
- MeSH terms
- Aged, Alzheimer Disease, Carbamazepine, Double-Blind Method, Drug Resistance, Hostility, Humans, Brief Psychiatric Rating Scale, Pilot Projects, Psychomotor Agitation, Severity of Illness Index, Antipsychotic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
